ATARA Biotherapeutics (ATRA) Misses Q2 EPS by 18c

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/5/2026

1. PTC
2. NVDA
3. PCVX
4. SPY
5. META
6. MSFT
7. GOOGL
8. GMAB
9. USO
10. AMD

Go back to ATARA Biotherapeutics (ATRA) Misses Q2 EPS by 18c

Atara Biotherapeutics Announces Second Quarter 2015 Results

August 6, 2015 6:30 AM EDT

SOUTH SAN FRANCISCO, Calif., Aug. 6, 2015 (GLOBE NEWSWIRE) -- Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a biopharmaceutical company with a focus on developing innovative therapies for patients with debilitating diseases, today reported financial results for the second quarter ended June 30, 2015.

Second Quarter 2015 Strategic and Operational Highlights

Licensed from Memorial Sloan Kettering Cancer Center (MSK) exclusive, world-wide rights to three clinical stage, allogeneic T-cell therapies for the treatment of cancers and persistent viral infections. Met with the FDA to discuss the design of registration studies for T-lymphocytes activated against Epstein-Barr Virus (EBV-CTL)... More